Cat’s Claw & Kava Hidden-Opioid Products: Evidence, Overdose, Dependence & Product-Safety Monograph

Cat’s Claw & Kava Products With Hidden Opioids: What Poison Centers Are Warning About

Emergency warning: If someone cannot be awakened, has slow/irregular/stopped breathing, blue or gray lips/skin, gurgling/choking, or collapses after a smoke-shop “Cat’s Claw,” “Kava,” or proprietary botanical product, call emergency services and give naloxone if available. Do not wait for the exact ingredient to be identified.

Important distinction: Genuine Cat’s Claw and genuine Kava are not the same thing as smoke-shop products that use those botanical names while containing or being suspected of containing undisclosed opioid-active compounds.

Quick answer

In 2026, poison centers began warning about a specific product-market problem: some flavored tablets, shots, and “proprietary botanical extracts” marketed with Cat’s Claw or Kava branding were associated with opioid-like overdose, dependence, and withdrawal.

Utah Poison Control named Buzzers and Homiez among products of concern. A separate Utah Department of Agriculture and Food investigation went further and reported that tested Buzzers Cat’s Claw tablets contained MGM-15 and mitragynine pseudoindoxyl.

The correct conclusion is not “Cat’s Claw is an opioid.”

It is that a botanical label may not reliably describe the pharmacologically important ingredients in an unregulated product.

Market history: how the warning developed

The modern concern did not begin with traditional Cat's Claw or Kava pharmacology. It emerged from a 2025–2026 consumer-product pattern in which smoke-shop and online products used familiar botanical branding while producing clinical effects inconsistent with the named herb.

By 2026, the evidence had separated into two important streams:

• national poison-center surveillance showing increasing kava exposure reports and more kava/kratom co-exposure; and
• product-specific state investigations, including Utah laboratory confirmation of MGM-15 and mitragynine pseudoindoxyl in tested Buzzers Cat's Claw tablets.

The market then changed again when federal control of pseudoindoxyl and MGM-15 took effect in August 2026.

This chronology is why a current article must date its claims. A 2025 label, archived COA, or retailer listing can describe a different regulatory and product environment from an October 2026 safety review.

The four evidence lanes: do not collapse them

This market is unusually easy to describe badly. Every product claim should be assigned to one of four lanes:

The Utah Buzzers finding belongs in lane 1. The broader Homiez warning belongs primarily in lane 2 unless product-specific analytical results are published. “No kratom” or “no 7-OH” on a package belongs in lane 3. Reddit reports belong in lane 4.

This framework prevents one tested tablet from becoming an unsupported claim about an entire retail category.

Genuine botanicals: what Cat’s Claw and Kava actually are

Cat’s Claw

Genuine Cat’s Claw generally refers to Uncaria tomentosa or related Uncaria species. Its characteristic chemistry centers on plant alkaloids such as oxindole alkaloids—not MGM-15 or mitragynine pseudoindoxyl.

Kava

Genuine Kava is Piper methysticum. Its principal psychoactive constituents are kavalactones, which can produce CNS-depressant effects but are pharmacologically distinct from mu-opioid agonists such as MGM-15 or pseudoindoxyl.

This distinction matters clinically: sedation after genuine kava is not proof of an opioid, while profound respiratory depression or naloxone-responsive toxicity in an oddly branded product should raise concern for an unexpected opioid or mixed exposure.

The wider kava market: what CDC surveillance does and does not show

A 2026 CDC/MMWR analysis of National Poison Data System data provides important background but answers a different question from the Utah Buzzers testing.

In 2025:

• U.S. poison centers received 203 kava exposure reports;
• 61 (30%) involved both kava and kratom;
• serious medical outcomes were reported in 32% of kava exposure reports, compared with 12% in 2000.

The surveillance shows increasing kava-related reports, growing kava/kratom co-exposure, and more serious reported outcomes. It does not establish that those 203 reports involved MGM-15, pseudoindoxyl, Buzzers, or hidden opioids.

That distinction is exactly why product-specific chemistry and national poison-center surveillance belong in separate evidence lanes.

Genuine Cat’s Claw vs products labeled “Cat’s Claw extract”

Cat’s Claw usually refers to Uncaria tomentosa, an Amazonian vine containing oxindole alkaloids.

Traditional Cat’s Claw products are not expected to produce the profound opioid-like effects reported in the 2026 poison-center cases.

This distinction matters because consumers searching for the herb for joint, inflammatory, or general supplement purposes should not be led to believe that every product using the words “Cat’s Claw” carries the same opioid concern.

The concern is concentrated in a specific emerging smoke-shop / online product category where the label, pharmacology, and analytical testing may not line up.

What Utah Poison Control warned about

Utah Poison Control reported multiple cases of severe overdose associated with products containing blends marketed around Kava or Cat’s Claw.

The center warned that products could contain kratom-derived opioid compounds such as:

• 7-hydroxymitragynine;
• mitragynine pseudoindoxyl;
• MGM-15;
• MGM-16.

At the time of the initial warning, investigation and testing were ongoing.

The key point is that poison centers were responding to a clinical pattern—profound opioid-like toxicity in people who thought they had used a botanical product.

What was actually confirmed by laboratory testing?

Utah’s July 30 follow-up announcement gave the strongest specific result.

Tested Buzzers-branded Cat’s Claw tablets were reported to contain:

• MGM-15
• mitragynine pseudoindoxyl

That confirmed that at least some products sold under a Cat’s Claw label contained potent opioid-active kratom derivatives not expected from ordinary Uncaria tomentosa.

The finding should not be automatically generalized to every Cat’s Claw product, every Buzzers batch, or every brand named in an earlier warning.

What about Homiez?

Utah Poison Control named Homiez along with Buzzers in its broader warning about potentially adulterated Cat’s Claw/Kava products.

The sources used for this article do not establish the same product-specific laboratory result for Homiez that Utah reported for tested Buzzers tablets.

That difference matters. A public-health warning is evidence of concern; it is not the same thing as a published analytical confirmation for a specific batch.

Why online “lab results” can be misleading without being fake

A certificate of analysis can be real and still leave the most important question unanswered.

Imagine a panel that tests for:

• mitragynine;
• 7-OH;
• speciociliatine;
• speciogynine;
• several contaminants.

If the panel never tested for MGM-15, pseudoindoxyl, or another novel compound, a “non-detect” result cannot establish that those compounds are absent.

Always ask:

1. Which analytes were actually tested?
2. What was the detection or reporting limit?
3. Was an authentic reference standard used?
4. Does the sample/lab lot match the package in question?
5. Could the active ingredient fall outside the panel entirely?

Why Reddit matters—but only as an early-warning layer

Reddit threads have become a fast way to see what products people are encountering before formal literature catches up.

In the Cat’s Claw market, users repeatedly described:

• unexpected opioid-like effects;
• rapid tolerance;
• withdrawal;
• uncertainty about whether products contained MGM compounds;
• “non-detect” lab panels that did not test the suspected compounds.

Those reports are useful for identifying a signal.

They cannot determine chemical identity. Subjective similarity to 7-OH, fentanyl, tianeptine, buprenorphine, or MGM-15 does not prove what a tablet contains.

Emergency signs

Treat the situation as a possible opioid poisoning if a person becomes:

• impossible to wake;
• extremely sedated;
• slow or irregular in breathing;
• blue/gray around lips or fingertips;
• limp or collapsed;
• choking, snoring, or gurgling while unresponsive.

Call 911. Naloxone may reverse opioid toxicity and is appropriate when an opioid is suspected.

Dependence and withdrawal

Poison centers have also warned about dependence and withdrawal from these products.

That is biologically plausible when the active ingredient is a potent opioid agonist.

Because the exact identity and amount can vary, a person’s withdrawal course cannot safely be inferred from the package name.

For people using one of these products regularly, abrupt changes can be difficult and sometimes medically complicated—especially when other sedatives, opioids, alcohol, or medical conditions are involved.

Pharmacokinetics: why there is no product-level PK curve

A branded category such as “Cat's Claw extract,” “Kava blend,” Buzzers, or Homiez does not have one meaningful pharmacokinetic profile when the active ingredients are unknown, undisclosed, or batch-variable.

Pharmacokinetics belong to specific molecules at specific exposures.

For example:

• genuine kavalactones have one set of absorption/metabolism questions;
• MGM-15 has a different and poorly characterized human PK profile;
• mitragynine pseudoindoxyl has another;
• an unknown mixture cannot inherit the half-life of whichever ingredient a user suspects.

Therefore no responsible article can give a brand-level onset, half-life, clearance time, accumulation model, or withdrawal clock without analytically establishing the active compounds first.

This is an explicit evidence gap—not missing editorial work.

Dependence, withdrawal, and addiction education

If a mislabeled product contains a potent opioid agonist, the nervous system can adapt to repeated exposure even when the consumer did not knowingly choose an opioid.

Physical dependence

Physical dependence means stopping or sharply reducing exposure produces withdrawal. It can occur without compulsive behavior.

Substance use disorder

A substance use disorder is broader and can include:

• craving;
• inability to cut down;
• escalating use;
• using to avoid withdrawal;
• continued use despite overdose or health harm;
• interference with work, relationships, or responsibilities;
• substantial time spent obtaining, using, or recovering.

Someone can become opioid-dependent through a misleadingly labeled product and feel confused because the package does not match the symptoms. The label does not change the underlying physiology.

What withdrawal might look like

When an opioid-active compound is responsible, symptoms can include restlessness, sweating/chills, insomnia, gastrointestinal upset, muscle aches, anxiety, rapid pulse, and strong craving.

There is no validated Buzzers-, Homiez-, Cat’s Claw-brand-, or Kava-brand-specific withdrawal timeline. The actual ingredient, concentration, co-ingredients, duration of use, and batch variability may be unknown.

Treatment and support

A person with repeated withdrawal, escalating use, inability to stop, or continued use despite harm can seek addiction-medicine care even if the exact product chemistry is unknown.

When the syndrome is opioid-like, clinicians can evaluate established opioid-use-disorder treatments rather than waiting for a brand-specific clinical trial. This page does not provide DIY induction or taper schedules.

U.S. resources:

• FindTreatment.gov
• SAMHSA National Helpline: 1-800-662-HELP (4357)

Severe sedation, abnormal breathing, collapse, serious dehydration, chest pain, confusion, pregnancy with significant withdrawal, or suicidal thoughts require urgent medical evaluation.

Testing and toxicology

Routine toxicology can be falsely reassuring in this market.

A conventional hospital or workplace panel might include fentanyl, common opiates, benzodiazepines, stimulants, or THC while not including MGM-15, pseudoindoxyl, MGM-16, or other emerging kratom-derived opioids.

More definitive investigation can require:

• targeted LC-MS/MS;
• high-resolution mass spectrometry;
• appropriate reference standards;
• a sufficiently broad analyte library;
• product testing in addition to biological testing.

A negative fentanyl test answers one question: fentanyl was not detected by that method above its reporting threshold. It does not answer whether an unfamiliar opioid was present.

How to read a certificate of analysis

A useful COA should be treated as a bounded analytical result, not a guarantee.

Ask:

• Which exact compounds were included?
• Was MGM-15 specifically included?
• Was mitragynine pseudoindoxyl specifically included?
• What were the detection/reporting limits?
• What method was used?
• Were reference standards available?
• Is the tested lot the same as the product in hand?
• Does the panel address only potency/alkaloids, or also contaminants/adulterants?

“No 7-OH detected” is not logically equivalent to “no opioid present.”

Forensic interpretation and causality

A product associated with an overdose or death can be relevant without being proven the sole cause.

Interpretation should distinguish:

• what the package claimed;
• what the product sample actually contained;
• what was detected in biological specimens;
• what other drugs were present;
• whether the medical examiner assigned cause or contribution;
• whether the result applies to the tested batch or the whole brand.

The Utah investigation's strongest product-specific conclusion is that tested Buzzers Cat’s Claw samples contained MGM-15 and pseudoindoxyl. The associated death and severe events are important safety signals, but a public-health announcement should not be converted into an unsupported universal fatality rate or “fatal dose.”

Interactions and mixed-product risk

Unknown product composition makes interaction prediction especially difficult.

Potentially serious combinations include unexpected opioid-active compounds plus:

• alcohol;
• benzodiazepines;
• prescription/illicit opioids;
• gabapentinoids;
• sedative-hypnotics;
• genuine kava or other sedating ingredients.

The concern is compounded respiratory/CNS depression, not a recreational “combination effect.”

Special populations

There are no adequate clinical studies of these adulterated product categories in pregnancy, breastfeeding, adolescents, older adults, respiratory disease, seizure disorders, or significant liver/kidney disease.

For unknown mixtures, missing evidence is an uncertainty signal rather than proof of safety.

Myths and evidence corrections

“Cat’s Claw is secretly an opioid.”
No. Genuine Uncaria is not MGM-15 or pseudoindoxyl. The problem is mislabeled/adulterated retail products.

“Kava overdose reports prove kava contains hidden opioids.”
No. CDC surveillance includes genuine kava, co-use, and mixed products and does not chemically identify an opioid in every report.

“No kratom / no 7-OH means opioid-free.”
No. A different opioid-active derivative can be present.

“A real COA means the entire product is known.”
No. A COA is only as complete as its analyte list, method, sample, and lot.

“If naloxone works, we know which opioid was present.”
No. A clinical response supports opioid physiology; it does not identify a molecule.

“Every Buzzers or Homiez product has been proven to contain MGM-15.”
No. The strongest public laboratory confirmation described here applies to tested Buzzers Cat’s Claw products. Homiez was named in a broader poison-center warning.

Evidence ledger

Bottom line

The 2026 Cat’s Claw/Kava warnings are not evidence that traditional botanical Cat’s Claw or Kava secretly behaves like an opioid.

They are evidence of a label-integrity problem in an emerging consumer-drug market.

Utah authorities confirmed MGM-15 and mitragynine pseudoindoxyl in tested Buzzers Cat’s Claw tablets, while poison centers warned that other similarly marketed products may also pose opioid-overdose risks.

The safest assumption is that an unverified “proprietary botanical extract” is pharmacologically unknown until the relevant active compounds have actually been tested.

Related evidence

• Buzzers Cat’s Claw tablets: what testing found
• MGM-15
• Mitragynine pseudoindoxyl
• 7-Hydroxymitragynine
• Substance Use, Dependence & Harm Reduction hub